Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Revolution Medicines, Inc.
Study ID
NCT07491445
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • daraxonrasib — DRUG
    oral tablets
  • gemcitabine — DRUG
    intravenous (IV) infusion
  • nab-paclitaxel — DRUG
    IV infusion

Study Details

The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

Key Dates

Start date
Mar 9, 2026
Status verified
Jun 2026
Primary completion
Jun 30, 2028
Completion
Mar 31, 2029

Study Design

Enrollment
900 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: daraxonrasib
    study drug
  • Experimental: Arm B: daraxonrasib + gemcitabine and nab-paclitaxel
    study drug in combination with chemotherapy
  • Active Comparator: Arm C: gemcitabine and nab-paclitaxel
    SOC chemotherapy

Primary Outcome Measure

Progression free survival (PFS) [ Time Frame: Up to approximately 2 years ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Johns Hopkins Sidney Kimmel Comprehensive Cancer CenterBaltimoreMaryland21287
Memory Maunde
[email protected]
410-955-8152
Dana-Farber Cancer InstituteBostonMassachusetts02215
Brian Wolpin
[email protected]
857-215-2351
Comprehensive Cancer Centers of NevadaHendersonNevada89052
Ann Lovelace
[email protected]
702-609-9460
Taylor Cancer Research CenterMaumeeOhio43537
Stephanie Ambrose
[email protected]
567-402-4502
Virginia Mason Medical CenterSeattleWashington98101
Das Rishika
[email protected]
206-287-6273

Find similar trials in Baltimore, MD

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center· Baltimore, MDDana-Farber Cancer Institute· Boston, MAComprehensive Cancer Centers of Nevada· Henderson, NVTaylor Cancer Research Center· Maumee, OHVirginia Mason Medical Center· Seattle, WA

Related Studies